Phase II study of spirogermanium in advanced breast cancer.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000633:toxicity*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D005857:Germanium / Q000627:therapeutic use / Q000633:toxicity*; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds; D011960:Receptors, Estrogen; D013141:Spiro Compounds / Q000627:therapeutic use / Q000633:toxicity*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D011960:Receptors, Estrogen; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium